Straits Times Index
3,292.70 +26.75 (+0.82%) Nikkei
38,164.01 +90.03 (+0.24%) Hang Seng
18,859.60 +321.79 (+1.74%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,962.21 +1,464.07 (+2.38%) CMC Crypto 200
1,352.64 +52.54 (+4.04%)
ClearPoint Neuro, Inc. (CLPT)
After hours:
| Previous close | 5.99 |
| Open | 5.94 |
| Bid | 6.06 x 100 |
| Ask | 6.13 x 400 |
| Day's range | 5.86 - 6.18 |
| 52-week range | 4.05 - 9.31 |
| Volume | |
| Avg. volume | 161,091 |
| Market cap | 165.395M |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.90 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- GuruFocus.com
ClearPoint Neuro Inc (CLPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ...
ClearPoint Neuro showcases a 41% revenue increase and strategic expansions in biologics and capital equipment sectors.
GlobeNewswireClearPoint Neuro Reports First Quarter 2024 Results
First Quarter Revenue Growth +41%; Record Revenue AchievedSOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights Reported quarterly revenue of $7.6 million, a 41% year-over-year increase;Increased biologics and drug delivery revenue
- GlobeNewswire
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held in Baltimore, MD from May 7-11. The following original research abstracts will be presented at the Poster Session: De-Risking Clinical Trials Le
